Avanir Pharmaceuticals (NASDAQ: AVNR) is dedicated to acquiring, developing, and commercializing innovative therapeutic products designed to treat chronic diseases. Zenvia™, the company’s lead product candidate, is currently being developed to treat pseudobulbar affect (PBA). GlaxoSmithKline Consumer Healthcare currently markets Avanir’s first commercialized product, Abreva®, in North America. Abreva is the leading over-the-counter product for the treatment of cold sores. For further information, visit the Company’s web site at www.avanir.com.
- 18 years ago
QualityStocks
Avanir Pharmaceuticals (NASDAQ: AVNR)
Tags Rodman & Renshaw
Related Post
-
Quantum BioPharma Ltd. (NASDAQ: QNTM) Pursues a New Path for Better Multiple Sclerosis Treatments
In the United States alone, close to one million people are living with MS, with…
-
Why Verbal Skills Aren’t Enough: WRAP’s New Doctrine Aims to Give Officers a Lawful Next Step
California's SB 230 requires agencies to incorporate de-escalation and alternatives to force into their use-of-force…
-
Beeline Holdings Inc. (NASDAQ: BLNE) Partners with Loft 100 Studios to Examine the Mortgage Market and New Approaches to Homeownership
The partnership will focus on the production of a 45-minute “Bizumentary” examining current challenges and…